Key result
Reviparin sodium is as effective as unfractionated heparin for DVT prophylaxis in surgical patients and more effective for thrombus reduction in acute venous thromboembolism.
Why the study?
Does reviparin sodium prevent DVT and PE as effectively as unfractionated heparin in surgical and VTE patients?
Does reviparin sodium prevent DVT and PE as effectively as unfractionated heparin in surgical and VTE patients?
Reviparin is an effective low molecular weight heparin alternative to unfractionated heparin for the prevention and treatment of venous thromboembolism, with a potentially better safety profile.
Answers are grounded in this paper and cite their sources.
May support reviparin as LMWH alternative for VTE; leaves open contemporary RCTs versus current standards.
Reviparin sodium (Clivarine), Knoll AG) is a low molecular weight heparin (LMWH) with a mean peak molecular weight of 3900 Da. It is characterised by a narrow molecular weight distribution profile, with an anti-factor Xa (anti-Xa):anti-factor IIa (anti-IIa) ratio of >or=3.6. In healthy human volunteers, plasma anti-Xa activity was up to five times higher and lasted three times longer with reviparin compared with unfractionated heparin (UFH). Unlike UFH, reviparin has negligible effects on global clotting tests. Reviparin has been shown to be as effective as UFH in different prophylactic indications and causes fewer injection-site haematomas. At a daily dose of 1750 IU anti-Xa it was as effective as UFH in preventing deep vein thrombosis (DVT) in moderate risk surgery (general and abdominal) and significantly reduced DVT in patients with brace immobilisation of the legs. At a daily dose of 4200 IU anti-Xa reviparin was as effective as UFH or enoxaparin in preventing DVT in high risk orthopaedic surgery and as effective as UFH in prevention of DVT and/or pulmonary embolism (PE) and/or mortality in high risk orthopaedic surgery. In patients with acute venous thromboembolism (VTE), reviparin was more effective than UFH in thrombus reduction and at least as effective as UFH in the prevention of clinical recurrence of DVT and/or PE. The use of reviparin is associated with a similar or lower incidence of bleeding complications than UFH.
No takes yet. Share an insight, caveat, or question.
H.K. Breddin (2002) conducted a review in Deep vein thrombosis (DVT) and venous thromboembolism (VTE) prophylaxis and treatment. Reviparin sodium vs. Unfractionated heparin (UFH) or enoxaparin was evaluated. Reviparin sodium is as effective as unfractionated heparin for DVT prophylaxis in surgical patients and more effective for thrombus reduction in acute venous thromboembolism.
Synapse has enriched 10 related papers. Consider them for comparative context: